Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.38 |
| ▸ | MPO | P05164 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15880124 | 0.89 | ROCK1 (0.48) | ROCK1POLBTOP2AADRA1AHRH1 | |
| SCHEMBL17321546 | 0.86 | ROCK1 (0.47) | ROCK1POLBTOP2AADRA1AHRH1 | |
| SCHEMBL15880333 | 0.85 | ROCK1 (0.48) | ROCK1POLBTOP2AADRA1AHRH1 | |
| SCHEMBL17981694 | 0.84 | ATM (0.56) | ATMPTGER4MPOHPGDKDM4E | |
| SCHEMBL18073156 | 0.84 | ALDH1A1 (0.48) | POLBATMPTGER4MPOHPGD | |
| SCHEMBL17981714 | 0.79 | MPO (0.46) | ATMPTGER4MPOKDM4EALDH1A1 | |
| SCHEMBL17324739 | 0.75 | KDM5A (0.42) | ATMHPGDKDM4EALDH1A1ADORA3 | |
| SCHEMBL17324780 | 0.74 | ROCK1 (0.48) | ROCK1POLBTOP2AADRA1AHRH1 | |
| SCHEMBL4843204 | 0.72 | TOP2A (0.42) | ROCK1TOP2AADRA1AHRH1ADRA1B | |
| SCHEMBL19997237 | 0.72 | KAT2B (0.47) | ROCK1PTGER4MPOHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926282-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3252049-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252050-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | ROCK1 3/4885POLB 3821/4885TOP2A 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.